PRVB News and Press, Provention Bio Inc. From 06/18/20

Provention Bio (NASDAQ: PRVB )  +1%   prices its public offering of 6.6M common shares at $14.50 per share for gross proceeds of $95.7M. More news on: Provention Bio, Inc., Healthcare stocks news, , Read more ...

OLDWICK, N.J. , June 17, 2020 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the pricing of its previously announced underwritten public offering of 6,600,000 shares of it...

Shares of Provention Bio (NASDAQ: PRVB) , a clinical-stage biotech company, fell by about 7% on Wednesday, following the company's announcement that it would initiate a public offering of common stock. Provention Bio made this announcement on Tuesday afternoon. Naturally, investors aren't too...

Gainers:  INWK +46.6% . FLGT +9.3% . GRPN +4.7% . STWD +4.6% . MG +4.2% . More news on: InnerWorkings, Inc., Fulgent Genetics, Inc., Groupon, Inc., Stocks on the move, , Read more ...

Shares of Proventio Bio (NASDAQ: PRVB) -- a clinical-stage biotech company -- jumped by 9.4% on Monday after the drugmaker reported positive data from a clinical trial for one of its lead pipeline candidates, teplizumab (PRV-031).  Proventio Bio has big ambitions: The company is lookin...

Provention Bio ( PRVB +10.6% ) is up on a 4x surge in volume in reaction to follow-up data from a Phase 2 study, "At Risk" TN-10 , evaluating teplizumab for preventing/delaying the onset of type 1 diabetes (T1D) in relatives of type 1 diabetics deemed "at very high risk" of developing t...

OLDWICK, N.J. , June 15, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced extended follow-up data showing a single 14-day course of teplizumab (PRV-031) significantly del...

OLDWICK, N.J. , May 28, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that management will present at the Jefferies Virtual Healthcare Conference on Thursda...

OLDWICK, N.J. , May 20, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced two changes to its board of directors. Nancy Wysenski has been a...

OLDWICK, N.J. and TAMPERE, Finland , May 18, 2020 /PRNewswire/ --  Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease and its licensor, Vactech Oy (Vactech), a Finnish biotechnology compan...